Coretag aims to obtain proof of concept of its probe in the clinic in the first half of 2020 and launch it in 2021 for clinical use
Necrosis occurs in the human body only in pathological conditions such as stroke, heart attack, burns, arthrosis or in the presence of an aggressively growing solid tumor. Coretag has developed a probe that specifically binds to necrotic cells in the human body. This feature permits detecting necrotic tissue. This is an important innovation, which can be used easily and effectively for many diagnostic and therapeutic purposes. This platform technology therefore offers great opportunity to develop diagnostic and therapeutic treatments.
Coretag products in the pipeline
After extensive pre-clinical research and development, The NC-Scan is now ready to enter the clinical phase. Although our platform technology offers various interesting applications, we first focus on four products:
FDA and EMA approval
A relative short time period is needed to have Coretag’s Necrosis Probe approved by the FDA and EMA, as it is a diagnostic drug. The Coretag probe can therefore be quickly implemented in clinical practice – improving the quality of care with major leaps and strictly controlling healthcare costs.